Doxorubicin

NOT RECOMMENDED AS AN ESSENTIAL MEDICINE

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc ATC codes: L01DB01

Indication	Unspecified malignant neoplasms of unspecified sites ICD11 code: 2D4Z
INN	Doxorubicin
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 10 mg in vial (hydrochloride) ; 50 mg in vial (hydrochloride)
EML status history	First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1982 (TRS 685) Changed in 2002 (TRS 914) Changed in 2003 (TRS 920) Changed in 2007 (TRS 950) Removed in 2015 (TRS 994)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Doxorubicin
DrugBank	Doxorubicin

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of doxorubicin was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for doxorubicin for more information.

